Trial reportClinical and translational science2012
Iron homeostasis during cystic fibrosis pulmonary exacerbation.
Trial report in Clinical and translational science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02188758 (Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2014Trial
- Absence of gut microbiota alleviates iron overload-induced colitis by modulating ferroptosis in mice.Journal of advanced research · 2025Article
- Improvement of iron status with elexacaftor tezacaftor ivacaftor therapy is associated with the correction of systemic inflammation and improvement of lung function: a one-year prospective study.Scientific reports · 2025Article
- EF-hand calcium sensor, EfhP, controls transcriptional regulation of iron uptake by calcium inmBio · 2024Article
- Drivers of diversification in fungal pathogen populations.PLoS pathogens · 2024Review
- Article
- Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung.bioRxiv : the preprint server for biology · 2023Article
- Iron bioavailability regulates Pseudomonas aeruginosa interspecies interactions through type VI secretion expression.Cell reports · 2023Article
- Iron Deficiency in Cystic Fibrosis: A Cross-Sectional Single-Centre Study in a Referral Adult Centre.Nutrients · 2022Article
- A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends.Scientific reports · 2021Observational
- Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis.Cell metabolism · 2020Article
- Perspectives on anemia and iron deficiency from the cystic fibrosis care community.Pediatric pulmonology · 2019Article
- Aerosolized Bovine Lactoferrin Counteracts Infection, Inflammation and Iron Dysbalance in A Cystic Fibrosis Mouse Model ofInternational journal of molecular sciences · 2019Article
- CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.Annals of the American Thoracic Society · 2019Article
- Serum Hepcidin Level as a Marker of Iron Status in Children with Cystic Fibrosis.Mediators of inflammation · 2018Article
- Effects ofAmerican journal of physiology. Cell physiology · 2017Review
- Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.Microbiology (Reading, England) · 2016Review
- Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.Clinical and translational science · 2015Article
- What is hepcidin telling us about the natural history of cystic fibrosis?Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHypoferremia is a marker of disease severity in cystic fibrosis (CF). The effect of systemic antibiotics on iron homeostasis during CF pulmonary exacerbation (CFPE) is unknown. Our central hypotheses were that, by the completion of treatment, serum iron would increase, serum concentrations of interleukin-6 (IL-6) and hepcidin-25, two mediators of hypoferremia, would decrease, and sputum iron would decrease.
methodsBlood and sputum samples were collected from 12 subjects with moderate-to-severe CF (median percentage-predicted forced expiratory volume in 1 second (FEV(1) %) = 29%; median weight = 56 kg) within 24 hours of starting and completing a course of systemic antibiotics.
resultsAfter treatment, subjects showed median FEV(1) % and body weight improvements of 4.5% and 2.0 kg, respectively (p < 0.05). Median serum iron rose by 2.4 μmol/L (p < 0.05), but 75% of patients remained hypoferremic. Median serum IL-6 and hepcidin-25 levels fell by 12.1 pg/mL and 37.5 ng/mL, respectively (p < 0.05). Median serum erythropoietin (EPO) and hemoglobin levels were unaffected by treatment. We observed a trend toward lower sputum iron content after treatment.
conclusionsHypoferremia is a salient characteristic of CFPE that improves with waning inflammation. Despite antibiotic treatment, many patients remain hypoferremic and anemic because of ineffective erythropoiesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.